Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$0.54
-$0.04(-9.27%)
At close: 4:00 PM EST
$0.54
-$0.04(-9.27%)
Day’s Range― - ―
52-Week Range$5.30 - $95.60
Previous CloseN/A
Volume845.14K
Average Volume (3M)17.77K
Market Cap
$4.00M
Enterprise Value$15.38
Total Cash (Recent Filing)$11.64M
Total Debt (Recent Filing)$23.38M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-88.00
Shares Outstanding720,531
10 Day Avg. Volume23,215
30 Day Avg. Volume17,775
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.75
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.78
Revenue Forecast (FY)$12.70M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained triple-digit revenue growth reflects accelerating commercial adoption of the LungFit platform across markets. Durable top-line momentum supports scaling of device placements and recurring consumable sales, improving prospects for long-term revenue conversion as install base grows.
High Customer Retention And Broader Commercial ReachA ~90% renewal rate plus multiple major GPO contracts and global clearances create durable distribution channels and recurring demand. Access to ~2,000 hospitals via GPOs and international regulatory footholds materially support repeat consumable revenue and long-term market penetration.
Gross-profit Swing And Cost-efficiency GainsImproved gross margins and sizeable SG&A/R&D reductions demonstrate meaningful operational leverage and a tighter cost base. Reduced cash burn and a move to gross profitability indicate the business is nearer to scalable economics if revenue growth persists, strengthening long-term viability.
Bears Say
Continued Large Net LossesDespite revenue and margin improvements, the company remains deeply loss-making, pressuring returns and shareholder equity. Persistent large net losses constrain reinvestment capacity and necessitate external funding, increasing execution risk over the medium term.
Constrained Liquidity And Ongoing Cash BurnLimited cash on hand versus sizable debt and a high burn rate creates a narrow runway absent financing or major revenue inflows. This structural liquidity pressure can force dilutive financings or slowed commercialization, undermining the firm's ability to execute multi-year growth plans.
Dependence On Gen 2 Approval And Listing ComplianceFuture revenue and TAM expansion hinge on FDA approval and timely Gen 2 launch, while Nasdaq compliance actions highlight listing risk. Combined regulatory and listing dependence concentrates execution risk: delays or an unsuccessful split/listing outcome would materially impede growth and financing access.
Beyond Air News
XAIR FAQ
What was Beyond Air’s price range in the past 12 months?
Beyond Air lowest stock price was $5.30 and its highest was $95.60 in the past 12 months.
What is Beyond Air’s market cap?
Beyond Air’s market cap is $4.00M.
When is Beyond Air’s upcoming earnings report date?
Beyond Air’s upcoming earnings report date is Aug 11, 2026 which is in 24 days.
How were Beyond Air’s earnings last quarter?
Beyond Air released its earnings results on Jun 26, 2026. The company reported -$15.4 earnings per share for the quarter, missing the consensus estimate of -$11.333 by -$4.067.
Is Beyond Air overvalued?
According to Wall Street analysts Beyond Air’s price is currently Overvalued.
Does Beyond Air pay dividends?
Beyond Air does not currently pay dividends.
What is Beyond Air’s EPS estimate?
Beyond Air’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyond Air have?
Beyond Air has 720,531 shares outstanding.
What happened to Beyond Air’s price movement after its last earnings report?
Beyond Air reported an EPS of -$15.4 in its last earnings report, missing expectations of -$11.333. Following the earnings report the stock price went up 3.708%.
Which hedge fund is a major shareholder of Beyond Air?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
62.97% Insiders
1.56% Mutual Funds
― Other Institutional Investors
35.04% Public Companies and
Individual Investors